Journals / Retina-Vitreus / 2018 / Cilt: 27 - Sayı: 4

Comparing Results of Intravitreal Afl ibercept and Ranibizumab Injections at Patients with Neovascular Age Related Macular Degeneration and Pigment Epithelial Detachment

Pigment Epitel Dekolmanı Bulunan Neovasküler Yaşa Bağlı Makula Dejenerasyonu Olgularında İntravitreal Afl ibercept ve Ranibizumab Yanıtlarının Karşılaştırılması

Pages
333–339
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: At AFL and RAN groups, after initial 3 doses of injections, the changes of morphological features were similar, RAN was better for BCVA changes.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Purpose: To evaluate the effects of three doses of intravitreal ranibizumab (RAN) and afl ibercept (AFL) on pigment epithelial detach- ment (PED) in neovascular age related macular degeneration (N-AMD).
📊
Key Findings & Data:Methods: We searched 92 patients’ data with PED and n-AMD.
💡
Conclusion & Impact:Conclusion: At AFL and RAN groups, after initial 3 doses of injections, the changes of morphological features were similar, RAN was better for BCVA changes.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Purpose: To evaluate the effects of three doses of intravitreal ranibizumab (RAN) and afl ibercept (AFL) on pigment epithelial detach- ment (PED) in neovascular age related macular degeneration (N-AMD). Methods: We searched 92 patients’ data with PED and n-AMD. The patients with RAP and PCV, irregular visits, the history of int- ravitreal injection or PDT were excluded. There were 13 patients at AFL and 11 patients at RAN group. Data on BCVA, CMT, PED types and height, intraretinal and subretinal fl uid were evaluated. Results: The mean CMT and BCVA were not signifi ciantly different between groups before injections (p> 0.05). At both groups the change of CMT was signifi ciantly different after injections (AFL p: 0.025, RAN p: 0.01). The BCVA change was not signifi ciantly different at AFL group (p: 0,063) but it was signifi ciantly different at RAN group (p: 0.007). After injections, PED height change was signifi ciantly different at each group (AFL p: 0.002, RAN p:0.003). The change of fi brovascular PEDs was similar to serous PEDs. Conclusion: At AFL and RAN groups, after initial 3 doses of injections, the changes of morphological features were similar, RAN was better for BCVA changes.

Özet

Amaç: Pigment epitel dekolmanına (PED) sahip neovasküler yaşa bağlı makula dejenerasyonunda (n-YBMD), üç yükleme dozu son- rasında afl ibercept (AFL) ve ranibizumab (RAN) yanıtlarının karşılaştırılması Gereç ve Yöntem: Mayıs 2015-Mayıs 2016 tarihleri arasında n-YBMD ve PED tanısı olan 92 hastanın bilgisine ulaşıldı. Retinal anjiyomatöz proliferasyon (RAP) ve polipoidal koroidal vaskülopati (PCV) tanısı olan hastalar, düzensiz takipler, önceden enjeksi- yon veya fotodinamik tedavi (PDT) yapılanlar çalışma dışı bırakıldı. Çalışma kriterlerine uygun ranibizumab (RAN) yükleme dozu yapılmış 13 hasta, afl ibercept (AFL) yapılmış 11 hasta değerlendirildi. En iyi düzeltilmiş görme keskinliği (EİDGK), santral makula kalınlığı (SMK), PED değişimleri, intraretinal (IRS) ve subretinal sıvı (SRS) durumları değerlendirildi. Bulgular: Gruplarda PED tipi (fi brovasküler veya seröz) dağılımı ve yüksekliği benzerdi. Enjeksiyonlardan önce SMK ve EİDGK açısından istatistiksel olarak anlamlı bir farklılık bulunmamaktaydı (p>0.05). SMK ortalamasındaki değişim enjeksiyon öncesi değer- lere göre sonrasında istatistiksel olarak anlamlıdır (AFL, p=0.025; RAN, p=0.001). EİDGK açısından ise; AFL grubunda istatistiksel olarak anlamlı bir değişim görülmemişken (p=0.063), RAN grubunda istatistiksel olarak anlamlıdır (p=0.007). PED yüksekliği deği- şimi; grupların içinde istatistiksel olarak anlamlıyken ( AFL, p=0.002; RAN, p=0.003 ), gruplar arasında fark bulunmamıştır. Fibro- vasküler ve seröz PEDler arasında tedaviye cevap açısından fark görülmemiştir. Sonuç: Her iki grupta da yükleme dozu sonrası morfolojik değişikliklerde benzer bir düzelme izlenirken, görme sonuçları açısından RAN daha etkili bulunmuştur.

🔖

Cite This Article

ALTINEL, M. G., KANRA, A. Y., ÖZKURT, Y. B. (2018). Comparing Results of Intravitreal Afl ibercept and Ranibizumab Injections at Patients with Neovascular Age Related Macular Degeneration and Pigment Epithelial Detachment. Retina-Vitreus, Cilt: 27 - Sayı: 4, 333–339. https://ajindex.com/articles/308122

References (12)

  1. Bressler NM. Age-related macular degeneration is the leading ca- use of blindness. JAMA 2004;291:1900-1
  2. Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, Sy JP, Schneider S; ANCHOR Study Group. Ranibizumab versus verteporfi n for neovascular age-related macular degenerati- on. N Engl J Med 2006;355:1432-44
  3. Rosenfeld PG, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY; MARINA Study Group. Ranibizumab for neovascular age- related macular degeneration. N Engl J Med 2006;355:1419-31
  4. Averyl RL, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, Giust MJ. Intravitreal bevacizumab (Avastin) for neovascular age- related macular degeneration. Ophthalmology 2006; 113:363-72
  5. Papadopoulos N, Martin J, Ruan Q, Rafi que A, Rosconi MP, Shi E, Pyles EA, Yancopoulos GD, Stahl N, Wiegand SJ. Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. An- giogenesis 2012;15:171-85
  6. Rakic J, Lambert V, Devy L, Luttun A, Carmeliet P, Claes C, Nguyen L, Foidart JM, Noël A, Munaut C. Placental growth fa- ctor, a member of the VEGF family, contributes to the develop- ment of choroidal neovascularization. Invest Ophthalmol Vis Sci 2003;44:3186-93
  7. Coscas F, Coscas G, Souied E, Tick S, Soubrane G. Optical co- herence tomography identifi cation of occult choroidal neovascu- larization in age-related macular degeneration. Am J Ophthalmol 2007;144:592-9
  8. Kalouda P, Anastasakis A, Tsika C, Tsilimbaris KM. The effect of intravitreal anti-VEGF on the pigment epithelial detachment in eyes with the exudative type of age-related macular degeneration. Semin Ophthalmol. 2015;30:6-10
  9. Ritter M, Bolz M, Sacu S, Deák GG, Kiss C, Pruente C, Schmi- dt-Erfurth UM. Effect of intravitreal ranibizumab in avascular pig- ment epithelial detachment. Eye. 2010;24:962-8
  10. Bakall B, Folk JC, Boldt HC, Sohn EH, Stone EM, Russell SR, Mahajan VB. Afl ibercept therapy for exudative age-related macu- lar degeneration resistant to bevacizumab and ranibizumab. Am J Ophthalmol 2013;156:15-22
  11. Ho VY, Yeh S, Olsen TW, Bergstrom CS, Yan J, Cribbs BE, Hub- bard GB. Short-term outcomes of afl ibercept for neovascular age- related macular degeneration in eyes previously treated with other vascular endothelial growth factor inhibitors. Am J Ophthalmol 2013;156:23-8
  12. Yonekawa Y, Andreoli C, Miller JB, Loewenstein JI, Sobrin L, Eli- ott D, Vavvas DG, Miller JW, Kim IK. Conversion to afl ibercept for chronic refractory or recurrent neova